| Literature DB >> 32786282 |
Camila Fontoura Acosta Ribeiro1, Gislaine Greice de Oliveira Silva Silveira1, Elizabete de Souza Cândido1,2, Marlon Henrique Cardoso1,2, Cristiano Marcelo Espínola Carvalho1, Octávio Luiz Franco1,2.
Abstract
The need for new antimicrobial therapies is evident, especially to reduce antimicrobial resistance and minimize deleterious effects on gut microbiota. However, although diverse studies discuss the adverse effects of broad-spectrum antibiotics on the microbiome ecology, targeted interventions that could solve this problem have often been overlooked. The impact of antibiotics on gut microbiota homeostasis is alarming, compromising its microbial community and leading to changes in host health. Recent studies have shown that these impacts can be transient or permanent, causing irreversible damage to gut microbiota. The responses to and changes in the gut microbial community arising from antibiotic treatment are related to its duration, the number of doses, antibiotic class, host age, genetic susceptibility, and lifestyle. In contrast, each individual's native microbiota can also affect the response to treatment as well as respond differently to antibiotic treatment. In this context, the current challenge is to promote the growth of potentially beneficial microorganisms and to reduce the proportion of microorganisms that cause dysbiosis, thus contributing to an improvement in the patient's health. An essential requirement for the development of novel antibiotics will be personalized medicinal strategies that recognize a patient's intestinal and biochemical individuality. Thus, this Review will address a new perspective on antimicrobial therapies through pathogen-selective antibiotics that minimize the impacts on human health due to changes in the gut microbiota from the use of antibiotics.Entities:
Keywords: antibiotics; antimicrobial therapies; bacterial diversity; dysbiosis; gut microbiota; microbial interaction; nontraditional antimicrobial therapies
Mesh:
Substances:
Year: 2020 PMID: 32786282 DOI: 10.1021/acsinfecdis.0c00036
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084